Comparison the effect of intranasal ketamine hydrochloride and intravenous morphine sulfate on pain severity of patients with upper or lower limbs fracture

Comparsion the effect of intranasal ketamine hydrochloride and intravenous morphine sulfate on pain severity of patients with limb fracture

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016031027007N1

Enrollment

104

Registered

2016-05-28

Start date

2016-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain. Pain in limb

Interventions

Intervention 1: Patients in intranasal ketamine hydrochloride group will receive 1 mg/kg ketamine hydrochloride of 10 ml solution (which put in sterile nasal drop bottle) via inhalation. Intervention

Treatment - Drugs

Patients in intranasal ketamine hydrochloride group will receive 1 mg/kg ketamine hydrochloride of 10 ml solution (which put in sterile nasal drop bottle) via inhalation.

Patients in intravenous morphine sulfate group will receive 0.1 mg/kg morphine sulfate via intravenous

Eligibility

Sex/Gender

All

Age

15 Years to 64 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age range of 15 to 64 years; having upper and lower limbs fracture. Exclusion criteria: low of consciousness; hemodynamic instability; addiction to drugs or opioids; mental retardation and psychosis; chronic cardiovascular diseases; being pregnant and breastfeeding; intranasal ketamine hydrochloride and intravenous morphine sulfate contraindication.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain severity. Timepoint: Before intervention and 5, 10, 15, 20, 25 and 30 minutes after intervention. Method of measurement: Visual analog scale.	—

Secondary

Measure	Time frame
Vital sign. Timepoint: Before intervention and 5, 10, 15, 20, 25 and 30 minutes after intervention. Method of measurement: Cardiopulmonary monitoring.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayyeh Gharibi

Ahvaz Imam Khomeini hospital

Dr.s.gharibi@gmail.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026